Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Giorgia Peverelli"'
Autor:
Emma Zattarin, Federico Nichetti, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fucà, Giorgia Peverelli, Andrea Vingiani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Extramammary Paget disease (EMPD) is a rare form of cutaneous, intraepithelial adenocarcinoma, which typically presents itself as an erythematous plaque originating from apocrine-gland rich regions, such as the vulva, the perianal region, the scrotum
Externí odkaz:
https://doaj.org/article/02ed4f0921e249db898877b9b34d54a9
Autor:
Riccardo Lobefaro, Emma Zattarin, Federico Nichetti, Michele Prisciandaro, Francesca Ligorio, Marta Brambilla, Pierangela Sepe, Francesca Corti, Giorgia Peverelli, Arianna Ottini, Teresa Beninato, Laura Mazzeo, Carmen G. Rea, Gabriella Mariani, Filippo de Braud, Giulia V. Bianchi, Claudio Vernieri, Giuseppe Capri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration of neoadjuvant ChT has been poorly investigated so far. Materia
Externí odkaz:
https://doaj.org/article/c3073977056545c1a2af193174e6c1be
Autor:
Claudio Vernieri, Michele Prisciandaro, Federico Nichetti, Riccardo Lobefaro, Giorgia Peverelli, Francesca Ligorio, Emma Zattarin, Maria Silvia Cona, Pierangela Sepe, Francesca Corti, Sara Manglaviti, Marta Brambilla, Barbara Re, Antonino Belfiore, Giancarlo Pruneri, Luigi Celio, Gabriella Mariani, Giulia Valeria Bianchi, Licia Rivoltini, Giuseppe Capri, Filippo de Braud
Publikováno v:
Cancers, Vol 12, Iss 3, p 617 (2020)
Background: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tol
Externí odkaz:
https://doaj.org/article/cccd6ffc20eb4fafa797d05db9ae3b15
Autor:
Riccardo Lobefaro, Luigi Mariani, Giorgia Peverelli, Francesca Ligorio, Giovanni Fucà, Alessandro Rametta, Emma Zattarin, Rita Leporati, Daniele Presti, Beatrice Cantarelli, Catherine Depretto, Andrea Vingiani, Siranoush Manoukian, Gianfranco Scaperrotta, Giulia V. Bianchi, Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri
Publikováno v:
Clinical breast cancer.
Platinum-based chemotherapy is widely used in patients with advanced triple-negative breast cancer (TNBC). However, the most effective platinum-based combination in the first-line treatment setting remains unclear.We evaluated the efficacy of first-l
Autor:
Giovanni Randon, Marco Maccauro, Melanie Claps, Filippo Pagani, Giulia Apollonio, Giorgia Peverelli, Giuseppe Procopio, Gianluca Aliberti, Alessandra Raimondi, Ettore Seregni, Pierangela Sepe, Elena Verzoni
Publikováno v:
Tumori Journal. 106:406-412
Introduction: Therapeutic decision-making in metastatic castration-resistant prostate cancer (mCRPC) represents an open challenge. Radium-223 is approved for patients with symptomatic bone metastases, no visceral involvement, progressing after at lea
Autor:
Sebastiano Buti, Giorgia Peverelli, Giuseppe Procopio, Luca Galli, Raffaele Ratta, Giacomo Cartenì, Giuseppe Fornarini, Marcello Tucci, Alessandra Raimondi, Elena Verzoni, Gaetano Facchini, Marco Bregni, Enrico Cortesi, Michele Prisciandaro
Publikováno v:
Clinical Genitourinary Cancer. 17:291-298
Background Cabozantinib showed efficacy and manageable toxicity in patients with metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to collect evidence on the potential efficacy of cabozantinib in mRCC patients
Autor:
Sarah Scagliarini, Michele Prisciandaro, Roberto Sabbatini, Giorgia Peverelli, Roberto Iacovelli, Giuseppe Procopio, Alessia Mennitto, Salvatore Caponnetto, Gaetano Facchini, Claudia Caserta, Giuseppe Fornarini, Elena Verzoni, Francesco Massari, Ugo De Giorgi, Raffaele Ratta
Publikováno v:
American Journal of Clinical Oncology. 42:42-45
The activity of cabozantinib in nonclear cell histologies has not been evaluated.Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperativ
Autor:
Federico Nichetti, Carmen G. Rea, Claudio Vernieri, Emma Zattarin, Gabriella Mariani, Riccardo Lobefaro, Giulia Bianchi, Filippo de Braud, Arianna Ottini, Giuseppe Capri, Francesca Ligorio, Pierangela Sepe, Teresa Beninato, Laura Mazzeo, Marta Brambilla, Giorgia Peverelli, Francesca Corti, Michele Prisciandaro
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background:Neoadjuvant anthracycline-taxane-based chemotherapy (ChT) is a standard of care treatment option for stage II–III breast cancer (BC) patients. However, the optimal duration of neoadjuvant ChT has been poorly investigated so far.Material
Autor:
Francesca Ligorio, Gabriella Mariani, Sara Manglaviti, Federico Nichetti, Marta Brambilla, Luigi Celio, Emma Zattarin, Barbara Re, Antonino Belfiore, Riccardo Lobefaro, Maria Silvia Cona, Francesca Corti, Giorgia Peverelli, Pierangela Sepe, Michele Prisciandaro, Filippo de Braud, Giulia Bianchi, Giuseppe Capri, Claudio Vernieri, Licia Rivoltini, Giancarlo Pruneri
Publikováno v:
Cancers
Volume 12
Issue 3
Cancers, Vol 12, Iss 3, p 617 (2020)
Volume 12
Issue 3
Cancers, Vol 12, Iss 3, p 617 (2020)
Background: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tol
Autor:
Alessandra Raimondi, Lorenza Rimassa, Francesca Bergamo, Carlotta Antoniotti, Matteo Clavarezza, Monica Niger, Vincenzo Adamo, Roberto Murialdo, Filippo Pietrantonio, Massimo Di Maio, Andrea Sartore-Bianchi, Giorgia Peverelli, Maria Antista, Saverio Cinieri, Monica Giordano, Fausto Petrelli, Marco Tampellini, Salvatore Corallo, Maria Di Bartolomeo, Sara Lonardi, Lorenzo Antonuzzo, Gianluca Tomasello, Filippo de Braud, Raffaella Longarini, Giuliana Ritorto, Federica Morano, Alberto Zaniboni
Background Quality of life (QoL) patient-reported outcomes (PROs) data from pivotal first-line trials in metastatic colorectal cancer (mCRC) are poor. The Valentino study showed that de-escalation to single-agent panitumumab after 4-month induction w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cece534f8a34f890c25303db0d3ec650
http://hdl.handle.net/2318/1770066
http://hdl.handle.net/2318/1770066